In collaboration with Drs. John Robbins and Rachel Schneerson at the Laboratory of Developmental and Molecular Immunology of the NICHD, we have developed a candidate conjugate vaccine that consists of Pfs25-Pfs25 conjugates. The immune sera induced by the conjugate vaccine displayed ability to block parasite development in mosquitoes. An Investigational New Drug Application was filed with FDA, intending a Phase 1 trial to test the safety, immunogenicity, and ex-vivo transmission blocking activity in humans. In response to FDAs comment, additional animal studies were conducted to evaluate the safety in animals.
Showing the most recent 10 out of 13 publications